NCT01516255已完成1 期
A Thorough QTc Evaluation of the Effect of Liraglutide on Cardiac Repolarization in Healthy Volunteers: A Randomized, Double-blind, Placebo-controlled, Two Period Crossover Study Followed by Open-label Moxifloxacin (Positive Control) Administration
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 64
- 试验地点
- 1
- 主要终点
- Maximum time-matched mean difference between the baseline subtracted QTci intervals
研究概览
简要总结
This trial is conducted in the United States of America (USA). The aim of this trial is to investigate if liraglutide effects the QTc interval. Moxifloxacin (Avelox®) is administered as positive control.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Fasting plasma glucose within normal limits (80-100 mg/dl)
- •BMI (Body Mass Index): 20.0-29.0 kg/m^2 (inclusive)
- •Heart rate within the range of 50-90 beats per minute (inclusive)
- •Subject is judged to be in good health on the basis of their medical history, physical examination, ECG (electrocardiogram), and routine laboratory data
排除标准
- •Any clinically significant disease history, in the opinion of the investigator, of systemic or organ disease
- •Any clinically significant disease history, in the opinion of the investigator, of cardiovascular disease
- •Clinically significant abnormalities on any pre-study clinical examination or any abnormal laboratory measurements during screening
- •A family history of sudden cardiac death at age less than 50 years old
- •T-wave abnormalities
- •Individual or familial history of long QT Syndrome
- •Positive results on Screening for Hepatitis B surface antigen, Hepatitis C antibody or HIV (human immunodeficiency virus) antibody
- •Positive results on the urine drug and alcohol screen
- •Any regular use of prescription or nonprescription drugs or vitamins and herbal/nutritional supplements that cannot be stopped at screening
- •Any strenuous exercise (as judged by the investigator) from 4 days prior to randomisation and during the entire trial period
- •Blood donation, trauma or surgery with blood loss exceeding 500 ml within the last 2 months prior to dosing
- •Subject is a smoker, occasional smoker or has a history of smoking (or use of any tobacco) within the last 3 months
- •Excessive use of methylxanthine-containing beverages (more than 8 cups/day of coffee, tea, soda or chocolate)
- •Females who are pregnant, breastfeeding, intend to become pregnant within the next 3 months, or who are judged to be using inadequate contraceptive measures
- •A history (within the last 2 years) of drug or alcohol abuse
研究组 & 干预措施
Double-blind / liraglutide
Experimental
干预措施: electrocardiogram (ECG) (Procedure)
Double-blind / placebo
Placebo Comparator
干预措施: placebo (Drug)
Double-blind / liraglutide
Experimental
干预措施: placebo (Drug)
Open-label / placebo
Placebo Comparator
干预措施: placebo (Drug)
Open-label / placebo
Placebo Comparator
干预措施: electrocardiogram (ECG) (Procedure)
Double-blind / placebo
Placebo Comparator
干预措施: electrocardiogram (ECG) (Procedure)
Open-label / moxifloxacin
Active Comparator
干预措施: electrocardiogram (ECG) (Procedure)
Double-blind / liraglutide
Experimental
干预措施: liraglutide (Drug)
Double-blind / placebo
Placebo Comparator
干预措施: liraglutide (Drug)
Open-label / moxifloxacin
Active Comparator
干预措施: moxifloxacin (Drug)
结局指标
主要结局
Maximum time-matched mean difference between the baseline subtracted QTci intervals
次要结局
- Vital signs: Pulse
- QTc at liraglutide tmax (time to reach maximum concentration)
- Percentage subjects with QTc at least 450, 480 and 500 milliseconds
- Cmax, maximum concentration of liraglutide
- Vitals signs: Blood pressure
- Serial electrocardiography
- tmax, time to reach Cmax of liraglutide
- Moxifloxacin maximum time-matched mean change QTc and QTci
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Effect and Safety of Liraglutide 3.0 mg as an Adjunct to Intensive Behaviour Therapy for Obesity in a Non-specialist SettingMetabolism and Nutrition DisorderObesityNCT02963935Novo Nordisk A/S282
已完成
3 期
Effect and Safety of Liraglutide 3.0 mg in Subjects With Overweight or Obesity and Type 2 Diabetes Mellitus Treated With Basal InsulinMetabolism and Nutrition DisorderObesityNCT02963922Novo Nordisk A/S396
已完成
3 期
The Effect of Liraglutide on Endothelial Function in Subjects With Type 2 Diabetes MellitusDiabetes Mellitus, Type 2DiabetesNCT00620282Novo Nordisk A/S49
已完成
3 期
Efficacy and Safety of Liraglutide Versus Placebo as add-on to Existing Diabetes Medication in Subjects With Type 2 Diabetes and Moderate Renal ImpairmentDiabetes Mellitus, Type 2DiabetesNCT01620489Novo Nordisk A/S279
已完成
3 期
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 DiabetesDiabetes Mellitus, Type 1DiabetesNCT01836523Novo Nordisk A/S1,398